АМИЛОИДОЗ СЕРДЦА: КЛИНИКА, ЛЕЧЕНИЕ, ПРОГНОЗ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Амилоидоз сердца (АС) - одно из самых тяжелых проявлений системного амилоидоза. Современная классификация амилоидоза основана на различиях амилоидогенных белков-предшественников. Таких белков в настоящее время известно около 30; соответственно, выделяют около 30 форм амилоидоза. В статье освещаются морфология и патогенез амилоидоза, нарушения функции сердца, прогноз в зависимости от варианта амилоидоза, кардиальных нарушений, уровня в крови маркеров повреждения кардиомиоцита, а также наличия и тяжести внесердечных проявлений амилоидоза. Представлено лечение системного амилоидоза в зависимости от варианта заболевания.

Полный текст

Доступ закрыт

Об авторах

Е. А Жданова

МГУ им. М.В. Ломоносова

аспирант кафедры внутренних болезней ФФМ Москва

В. В Рамеев

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздравсоцразвития

кандидат медицинских наук, ассистент кафедры терапии и профболезней МПФ Москва

С. В Моисеев

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздравсоцразвития

доктор медицинских наук, профессор кафедры терапии и профболезней МПФ Москва

Л. В Козловская

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздравсоцразвития

доктор медицинских наук, профессор кафедры терапии и профболезней МПФ Москва

А. Ф Сафарова

Российский университет дружбы народов

кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней медицинского факультета Москва

Список литературы

  1. Kyle R, Rajkumar S. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9(4):278-88.
  2. Shah K, Inoue Y, Mehra M. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;66( 1 7):1805-13.
  3. Connors B, Davidoff R, Skinner M, Falk R. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-29.
  4. Kyle R, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32(1):45-59.
  5. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57.
  6. Steiner I. The prevalence of isolated atrial amyloid. J Pathol 1987;153(4):395-98.
  7. Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-97.
  8. Ariyarajah P, Steiner I, Hajkova P, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009:113(2):132-37.
  9. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006;15(5):287-90.
  10. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62.
  11. Gillmore J, Booth D, Pepys M, Hawkins N. Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart 1999;82:2.
  12. Stangou A, Banner N, Hendry B, et al. Hereditary fibrinogen A-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 2010;115:2998-3007.
  13. Hamer M.J, Janssen S, Van Ruswuk M, Lie K. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echo-cardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13:623-27.
  14. Ha S, Kim W, Hwang S, et al. A case of systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. J Am Soc Echocardiogr 2009;22(5):542-47.
  15. Frenzel H, Schwartzkopff B, Kuhn H, et al. Cardiac amyloid deposits in endomyocardial biopsies. Light microscopic, ultrastructural, and immunohistochemical studies. Am J Clin Pathol 1986;85(6):674-80.
  16. Rapezzi C, Merlini G, Quarta C.C, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
  17. Sedlis S, Saffitz J, Schwob S, Jaffe A. Cardiac amyloidosis simulating hypertrophic cardiomyopathy. Am J Cardiol 1984;53:969-70.
  18. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57.
  19. Siqueira-Filho A, Cunha C, Tajik A, et al. M-mode and two-dimensional echocar-diographic features in cardiac amyloidosis. Circulation 1981;63:188-96.
  20. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-53.
  21. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594.
  22. Shi J, Guan J, Jiang В, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38 MAPK pathway. PNAS 2010; 107:4188-93.
  23. Truran S, Gutterman D, Schlundt B, et al. Oxidative stress and apoptotic injury induced by amyloidogenic light chain proteins in human coronary artery endothelial cells. Circulation 2010;122:16538.
  24. Perugini E, Rapezzi C, Piva T, et al. Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92: 343-49.
  25. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;31:754-65.
  26. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107: 2440-45.
  27. Hisaki R, Yutani C, Imakita M, et al. Histopathological study of valvular deposits of amyloid protein in cardiac amyloidosis. J Cardiol 1996;31:7.
  28. Vogelsberg H, Mahrholdt H, Deluigi C, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51: 1022-30.
  29. Volpi A, Cavalli A, Maggioni A, et al. Cardiac amyloidosis involving the conduction sys tem and the aortocoronary neuroreceptors. Clinicopathologic. correlates. Chest 1986;90:619-21.
  30. Ishikawa Y, Ishii T, Masuda S, et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int 1996;46(3):189-94.
  31. Suwaidi J.A, Velianou J, Gertz M, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999;131:838-41.
  32. Whitaker D, Tungekar M, Dussek J. Angina with a normal coronary angiogram caused by amyloidosis. Heart 2004;90:54.
  33. Perugini E, Guidalotti L, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
  34. Klein A, Hatle L, Taliercio C, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;16:1135-41.
  35. Demir M, Paydas S, Cayli M, et al. Tissue Doppler is a more reliable method in early detection of cardiac dysfunction in patients with AA amyloidosis. Ren Fail 2005; 27:415-20.
  36. Klein A, Hatle L, Taliercio C, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808-16.
  37. Cueto-Garcia L, Tajik A, Kyle R, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 1984;59(9):589-97.
  38. Falk R. Diagnosis and management of the cardiac amyloidosis. Circulation 2005;112(13):2047-60.
  39. Feng Da Li, Edwards W, Oh J. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420-26.
  40. Gertz M, Comenzo R, Falk R. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Blood (ASH Annual Meeting Abstracts) 2004;104:754.
  41. Klein A, Hatle L, Taliercio C. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808-16.
  42. Kristen A, Perz J, Schonland S, Hegenbart U. Non-invasive predictors of survival in cardiac amyloidosis. Europ J Heart Failure 2007;9:617-24.
  43. Dispenzieri A, Kyle R, Gertz M, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-89.
  44. Palladini G, Lavatelli F, Russo, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107: 3854-58.
  45. Herlenius G, Wilczek H, Larsson M, Ericzon B. Ten years of international experience with liver transplantation for familial amyloidot-ic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71.
  46. Lewis W, Skinner M, Simms R, et al. Orthotopic liver transplantation for familial amyloid-otic polyneuropathy. Clin Transplant 1994; 8:107-10.
  47. Parrilla P, Ramirez P, Andreu L, et al. Long-term results of liver transplantation in familial amy-loidoticpolyneuropathytypeI. Transplantation 1997;64:646-49.
  48. Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore) 2006; 85(4):229-38.
  49. Nardo B, Beltempo P, Bertelli R, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc 2004;36:645-47.
  50. Selvanayagam J, Hawkins N, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-10.
  51. Gertz M, Falk R, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channelblocking agents. Am J Cardiol 1985;55(13):1645.
  52. Griffiths B, Hughes P, Dowdle R, et al. Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 1982;37:711-12.
  53. Rubinow A, Skinner M, Cohen A. Digoxin sensitivity in amyloid cardiomyopathy. Circulation idosis: two cases with digitalis sensitivity. Ann Intern Med 1961;55:989-94.
  54. Austin B, Duffy B, Tan C, et al. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009; 103(10): 1429-33.
  55. Comenzo R. How I treat amyloidosis. Blood 2009;114:3147-57.
  56. Koch D, Sack F, Kristen A, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J CardiothoracSurg 2008;33:257-62.
  57. Kristen A, Sack F, Schonland S, Hegenbart U. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Europ J Heart Failure 2009;11:1014-20.
  58. Kpodonu J, Massad M, Caines A, Geha A. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24:1763-65.
  59. Kolstoea S, Mangionea P. Bellottia Trapping of palindromic ligands within native transthyretin prevents amyloid formation. PNAS 2010;107:20483-88.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2012